Bicycle Therapeutics plc (BCYC)

22,36 +0,51 (+2,33 %) À la clôture : 04:00PM EDT

Bicycle Therapeutics plc

Portway Building
Blocks A & B Granta Park Great Abington
Cambridge CB21 6GS
United Kingdom
44 1223 261 503
https://www.bicycletherapeutics.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 284

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Kevin Lee M.B.A., Ph.D.	CEO & Executive Director	1,35M	S.O.	1968
Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE	Co-Founder & Non-Executive Director	57,75k	S.O.	1951
Ms. Alethia Rene Young	Chief Financial Officer	581,69k	S.O.	1979
Dr. Santiago Arroyo M.D., Ph.D.	Chief Development Officer	916,98k	S.O.	1960
Dr. Christian Heinis	Scientific Founder	S.O.	S.O.	S.O.
Mr. Alistair Milnes	Chief Operating Officer	796,09k	S.O.	1974
Mr. Travis Thompson	Senior VP, Chief Accounting Officer & Principal Accounting Officer	S.O.	S.O.	S.O.
Dr. Michael Skynner B.sc. Ph.d., Ph.D.	Chief Technology Officer	881,01k	S.O.	1969
Dr. Nicholas Keen Ph.D.	Chief Scientific Officer	S.O.	S.O.	1968
Mr. Zafar Qadir	General Counsel	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Bicycle Therapeutics plc en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.